Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma.
The aim of this study was to investigate the relationship of cyclooxygenase (COX)-2 and p53 expression with prognosis in patients with conventional renal cell carcinoma (RCC). Formalin-fixed, paraffin-embedded tissue sections of conventional RCC from 92 patients, who had undergone radical nephrectomy, were examined for COX-2 and p53 expression by immunohistochemistry and compared with clinicopathological variables. The COX-2 expression significantly correlated only with tumor size (p=0.049), whereas the p53 expression profoundly correlated with the TNM stage (p=0.024), M stage (p=0.001), and metastasis (synchronous or metachronous; p=0.004). The COX-2 overexpression did not significantly associate with p53 positivity (p=0.821). The survival rate of patients correlated with the p53 expression (p<0.0001) but not with the COX-2 expression (p=0.7506). Multivariate analyses indicated that tumor size, M stage, and p53 expression were independent prognostic factors for cancer-specific survival. The COX-2 expression was not an independent factor. These results show that the increased expression of p53 was associated with metastasis and a worse prognosis in conventional RCC, which suggests that p53 might have played an important role in the progression of conventional RCC. The increased expression of COX-2 was associated only with tumor size, but may not be an important prognostic factor in conventional RCC. No association was observed between COX-2 overexpression and p53 positivity in conventional RCC.
Cho
Dae Sung
DS
Department of Urology, Ajou University School of Medicine, San-5, Wonchon- dong, Yeongtong-gu, Suwon 443-721, Korea.
Joo
Hee Jae
HJ
Oh
Dong Keun
DK
Kang
Ji Hun
JH
Kim
Young Soo
YS
Lee
Kyi Beom
KB
Kim
Se Joong
SJ
D014408:Biomarkers, Tumor / Q000378:metabolism*; D002292:Carcinoma, Renal Cell / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D051546:Cyclooxygenase 2; D006801:Humans; D007680:Kidney Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008565:Membrane Proteins; D011379:Prognosis; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
D014408:Biomarkers, Tumor; D008565:Membrane Proteins; D016159:Tumor Suppressor Protein p53; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases
J Surg Oncol. 1998 May;68(1):11-8
9610657
Annu Rev Pharmacol Toxicol. 1998;38:97-120
9597150
Oncogene. 1999 Dec 20;18(55):7908-16
10630643
Clin Cancer Res. 2000 Jun;6(6):2424-30
10873095
Cancer. 2000 Aug 1;89(3):589-96
10931458
Clin Cancer Res. 2000 Oct;6(10):4064-8
11051257
Vet Pathol. 2001 Jan;38(1):116-9
11199159
Urol Int. 2001;66(2):78-83
11223748
Clin Cancer Res. 2001 Apr;7(4):861-7
11309334
J Cell Physiol. 2002 Mar;190(3):279-86
11857443
Urology. 2002 Apr;59(4):615-20
11927338
Gynecol Oncol. 2003 Mar;88(3):379-85
12648590
Adv Exp Med Biol. 2002;507:123-6
12664575
Cancer Sci. 2003 Jan;94(1):22-5
12708469
Clin Cancer Res. 2003 May;9(5):1741-9
12738729
J Urol. 2003 Jun;169(6):2352-9
12771797
Cancer. 2003 Jun 15;97(12):2978-87
12784332
J Clin Gastroenterol. 2003 Jul;37(1):28-33
12811205
Int J Mol Med. 2004 Feb;13(2):229-33
14719128
Am J Surg Pathol. 1982 Oct;6(7):655-63
7180965
Cancer Res. 1995 Jan 15;55(2):237-41
7812951
Biochim Biophys Acta. 1996 Jan 5;1299(1):125-40
8555245
Anticancer Res. 1996 Nov-Dec;16(6B):3807-11
9042262
Eur Urol. 1997;32(1):110-7
9266242
Cancer. 1997 Sep 1;80(5):992-3
9307205
Cancer Res. 1998 Jan 15;58(2):362-6
9443418
Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):681-6
9435252
Semin Diagn Pathol. 1998 Feb;15(1):68-76
9503507
JAMA. 1999 May 5;281(17):1628-31
10235157